News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Industry Trends

>
  • IR Licensing and Partnerships

Latest News

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal
Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal
By Don Tracy, Associate Editor

May 19th 2025

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition
By Don Tracy, Associate Editor

May 16th 2025

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.

Earned Media and ASCO: Provide Context Beyond the Data
Earned Media and ASCO: Provide Context Beyond the Data
By Michael Christel

May 13th 2025

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
By Don Tracy, Associate Editor

May 13th 2025

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
By Don Tracy, Associate Editor

April 28th 2025

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

More News


The 2013 Pharm Exec Top 50

The 2013 Pharm Exec Top 50

Waseem Noor
May 1st 2013

Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.


i4-813748-1408538070322.gif

2013 Pharm Exec Top 50

May 1st 2013

Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.


Site Logo

Brand of the Year: Januvia

Ben Comer
March 1st 2013

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.


Industry Forecast 2013

Industry Forecast 2013

William Looney
January 25th 2013

As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.


Site Logo

2012: Year of Record

William Looney
December 1st 2012

The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry-for good or bad-in 2012.


Transforming Drug Development: A Lilly–Covance Case Study

Transforming Drug Development: A Lilly–Covance Case Study

December 1st 2012

Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.


Site Logo

Pharm Exec's 2013 Pipeline Report

Ben Comer
November 1st 2012

Is the 'lost decade' of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so...


Pharm Exec's 11th Annual Industry Audit

Pharm Exec's 11th Annual Industry Audit

Bill Trombetta
September 1st 2012

Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.


Emerging Pharma Leaders 2012

Emerging Pharma Leaders 2012

PE Staff
July 1st 2012

Meet the rest of 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history?


Site Logo

From the Editor:The Connections Game

William Looney
June 1st 2012

As the old Broadway song goes, June is busting out all over-and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.


Disruption in the C-Suite

Disruption in the C-Suite

Ben Comer
June 1st 2012

Clayton Christensen, author of "The Innovator's Dilemma", offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity.


Pharma 50 Comment: Seeding Beyond the Base

Pharma 50 Comment: Seeding Beyond the Base

William Looney
May 1st 2012

The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.


Pharm Exec 50: Growth from the Bottom Up

Pharm Exec 50: Growth from the Bottom Up

Patrick Clinton;Jerry Cacciotti
May 1st 2012

More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.


Profound Changes in the Outsourcing Landscape

Profound Changes in the Outsourcing Landscape

Kenneth Getz, MBA
February 29th 2012

Sponsor sourcing requirements are diverging from the operating needs and long-term strategies of the major CROs.


Biomanufacturing Outlook 2012

Biomanufacturing Outlook 2012

February 24th 2012

Preliminary results from BioPlan Associates' 9th Annual Report and Survey of Biomanufacturing suggest there's a good reason to be optimistic about 2012.


The Pharma Revolution Recalibrated

The Pharma Revolution Recalibrated

November 1st 2011

Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.


i4-744325-1408612664658.jpg

30 Years of Pharma: Perspective in Numbers, Part 3

October 1st 2011

Top 10 Companies by Market Share


Pharm Exec:  30 Years,  30 Leaders

Pharm Exec:  30 Years,  30 Leaders

William Looney
October 1st 2011

Pharm Exec celebrates its 30th birthday with a gathering of 30 of the industry's key influencers of the last three decades.


i4-744320-1408612677820.gif

30 Years of Pharma: Perspective in Numbers, Part 2

October 1st 2011

30 Years of Pharma: Perspective in Numbers


i4-744319-1408612680385.gif

30 Years of Pharma: Perspective in Numbers, Part 1

October 1st 2011

Top 10 Products Worldwide


12th Annual Pharm Exec 50

12th Annual Pharm Exec 50

May 1st 2011

Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies.


Keeping Your Place on the Nifty 50

Keeping Your Place on the Nifty 50

May 1st 2011

What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.


Pharm Exec Wins a Neal Award!

Pharm Exec Wins a Neal Award!

Jeff Schindler
April 1st 2011

William Looney, Editor-in-Chief, last month took home the award for "Best Commentary"


Pharm Exec's Seventh Annual Media Audit

Stephen J. Porth, PhD;George P. Sillup, PhD
March 1st 2011

Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation


Site Logo

Skipping the Needle: Pharm Exec's Brand of the Year

Jennifer Ringler
February 1st 2011

Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story


The Night Stalkers

The Night Stalkers

William Looney
January 1st 2011

"Tops in Fraud" is a ruinous moniker for pharma-a business so dependent on basic issues of trust, integrity, quality and safety


i1_t-703040-1408631003549.gif

The List: 2011

Walter Armstrong
January 1st 2011

It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!


Site Logo

Emerging Stakeholders with Clout: The Press Power Behind ProPublica

William Looney
December 1st 2010

The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica


The Next Wave: Pharm Exec's 2011 Pipeline Report

The Next Wave: Pharm Exec's 2011 Pipeline Report

December 1st 2010

42 of the best new drugs in development–or parked at the FDA


Nicotine Addiction: What Lights Up the Field

December 1st 2010

Pharm Exec's Pipeline Report 2018

<1
...
141516171819>
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.